NCT03732820 2026-01-29
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
AstraZeneca
Phase 3 Active not recruiting
Clinical Trials
1 trialsActive not recruiting × Has announcements × Metastatic Castration-resistant Prostate Cancer × Clear all